News related to
across

Richard Cheng, Associate Commercial Director (Hong Kong & Macau) at BeOne, said: “We are honored to receive this award from the Hong Kong Commercial Times. BeOne has built differentiated capabilities across clinical development and manufacturing, supported by a broad and diverse R&D pipeline. In Hong Kong, we have introduced several therapies, including BTK, PD-1 and IL-6 inhibitors. Looking ahead, we will continue to advance our plans in Hong Kong by leveraging opportunities enabled by the ‘1+’ policy and the planned establishment of the Hong Kong Centre for Medical Products Regulation (CMPR) and its ‘primary evaluation’ mechanism. Supported by our global supply network, we aim to bring additional medicines to patients in Hong Kong and the Greater Bay Area and help improve access to treatments aligned with international standards.”

Global R&D and Innovation

Founded in 2010, BeOne is focused on accelerating key stages of oncology innovation—from discovery through development to patient access. Through an integrated model spanning R&D, manufacturing and commercialization, the company works to translate innovation into clinical value. Today, BeOne operates across six continents in more than 45 markets and is supported by more than 1,200 oncology R&D professionals.

BeOne’s R&D platform has advanced more than 35 clinical-stage drug candidates, including three internally developed products that have received commercial approval, reaching more than 2 million patients worldwide.

Pipeline Highlights

BeOne continues to expand its global footprint through a portfolio of internally developed products, including:

• BTK Inhibitor: As the company’s first self-developed innovative drug, it holds a significant position in the global market (including Hong Kong), particularly in the field of B-cell malignancies.
• PD-1 Inhibitor: Launched in more than 50 markets worldwide, reaching 1.8 million people. In Hong Kong, it has been approved for six indications, including immunotherapy for lung, esophageal and gastric cancers.
• Next-Generation BCL-2 Inhibitor: Approved for certain lymphoma indications in Mainland China. It has been granted Priority Review by the U.S. Food and Drug Administration, and a marketing application has been submitted in the European Union.

Manufacturing Network Supporting Global Supply

BeOne maintains an integrated chain from R&D to manufacturing and commercialization, supported by production sites in the United States and China designed to help maintain a stable global supply:

• New Jersey, U.S.: A North America biologics hub integrating manufacturing and clinical R&D. The site spans 1.82 million square feet, including a dedicated 400,000-square-foot production facility.
• Suzhou, China (small molecule manufacturing): Supports clinical and commercial-scale production in accordance with applicable FDA, EMA and GMP requirements.
• Guangzhou, China (biologics and ADC manufacturing): A 1.3 million-square-foot facility supporting R&D and production of antibody-drug conjugates (ADCs) and serving as a supply hub for the Greater Bay Area, including Hong Kong.

BeOne has also been recognized by industry organizations for its innovation, including being named one of the “Top 10 Most Inventive” pharmaceutical companies by IDEA Pharma in 2025^[1]. The company will continue to advance programs in hematologic malignancies and solid tumors, with Hong Kong serving as a strategic hub to support the delivery of innovative therapies globally.

1. 2025 Pharmaceutical Innovation and Invention Index, IDEA Pharma

This material is intended for the purpose of communicating disease-related knowledge and cutting-edge medical information to the public and is not intended for promotional or advertising purposes. It does not constitute a promotion or recommendation for any medication or treatment plan, nor can it serve as a substitute for the advice of medical and health professionals. If you have any questions, please consult a medical or health professional.

Hashtag: #BeOneMedicines

https://www.beonemedicines.com/

The issuer is solely responsible for the content of this announcement.

About BeOne Medicines

BeOne Medicines is a global oncology company domiciled in Switzerland, focused on discovering and developing innovative treatments designed to be more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is advancing a diverse pipeline of novel therapeutics through internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to improving access to medicines for more patients. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

About HKCT Business Awards 2026

Organized by the Hong Kong Commercial Times, the HKCT Business Awards is a representative annual event in the Hong Kong business community. It honors companies demonstrating excellence, innovation, and significant contributions to Hong Kong’s economy and society across dimensions including technological innovation and market competitiveness.

Partnership pairs international leading longevity institution with HSBC’ to build the region’s first integrated “health and wealth” ecosystem for high‑net‑worth families.

HONG KONG SAR – Media OutReach Newswire – 11 May 2026 – Humansa, international leading integrated longevity institution and a premier destination for preventative healthcare, today announced the signing of a landmark Memorandum of Understanding (MoU) with The Hongkong and Shanghai Banking Corporation Limited (HSBC) and HSBC Life (International) Limited. This strategic collaboration aims to integrate advanced health optimisation with financial and insurance services, redefining how clients manage both their healthspan in Hong Kong and across the region.

A unified vision: healthspan as a core family asset

In a city renowned for its financial sophistication, the HSBC x Humansa alliance introduces a new paradigm: treating healthspan as a critical component of the modern family portfolio. As longevity science advances and demand for preventative healthcare accelerates, the partnership establishes a pioneering framework for an integrated “health and wealth” ecosystem designed specifically for high‑net‑worth and ultra‑high‑net‑worth clients.

Research from the Stanford Center on Longevity and other leading institutions highlights that many people in developed markets may live close to 100 years, making sustained cognitive and physical performance essential for a life of purpose and fulfilment. Simultaneously, global wealth reports show that affluent families are shifting spending from status goods toward wellness and longevity, and expect their financial partners to support this transition.

Moving beyond siloed services that treat health, wealth and insurance separately, Humansa contributes clinical excellence and geroscience‑based, data‑driven insights, while HSBC brings its wealth and insurance capabilities and a long‑term commitment to Asia as the world’s next major cross‑border wealth hub. Together, the parties aim to build the specialised infrastructure needed to manage health as a high‑value, appreciating asset over a 100‑year life.

Research‑driven excellence for high‑net‑worth clients

Humansa will lead the exploration of specialised longevity programs and dedicated physical spaces that combine clinical precision, behavioural coaching, and premium client experiences tailored to HSBC’s clients. By merging Humansa’s geroscience expertise with HSBC’s global wealth management reach and HSBC Life’s insurance capabilities, the partnership seeks to ensure that clients living longer – and better, at every stage of life.

Directives of the strategic collaboration: three pillars of “Longevity as an Asset”

Under the terms of the MoU, the parties have committed to three key pillars:

Longevity hubs and programs for HSBC clients – Explore the development of flagship “Longevity as an Asset” hubs and programs, where HSBC high-net-worth clients can access Humansa’s advanced diagnostics, health assessments and geroscience‑based services designed to preserve and grow their healthspan capital.

Integrated health‑wealth and insurance advisory – Pilot models where Humansa’s health insights can complement HSBC’s wealth and HSBC Life’s insurance advisory, enabling clients to align wealth management protection and succession strategies with their projected healthspan and personal goals.

Thought leadership and ecosystem building – Co‑create thought‑leadership platforms including research, client forums and CEO‑level dialogues in Hong Kong and other regional hubs to advance understanding of the economics of a 100‑year life, positioning Hong Kong at the forefront of longevity‑driven innovation.

These pillars provide a structured roadmap for turning the idea of “longevity as an asset” into practical offerings and experiences for clients across Asia.

“Humansa was founded on a simple belief: in a 100‑year life, healthspan is the most under‑managed asset on the family balance sheet,” said Don So, Chief Executive Officer of Humansa. “By joining forces with HSBC and HSBC Life, we are building the infrastructure that clients need to measure, protect and grow that asset – with clinical rigour, personalised programs and experiences that match the sophistication of their financial lives.

“Health, wealth and protection are deeply interconnected and shouldn’t be treated in isolation. As people live longer and spend more years beyond working life, they need trusted solutions to protect, grow and pass on their wealth — especially in an increasingly uncertain macro environment. Our partnership with Humansa brings together the best of both organisations to offer high net worth customers a seamless, one-stop health and wealth management solution.” said Daisy Tsang, Chief Executive Officer, HSBC Life Hong Kong and Macau.

“People are living longer, and that changes what ‘wealth planning’ really means. Our partnership with Humansa will help our clients treat healthspan as a core family asset, alongside their financial wealth, so they can stay well, stay active and keep their options open over a longer life. By combining Humansa’s longevity expertise with HSBC’s wealth capabilities, we’ll explore new ways to deliver a premium client experience that supports wellbeing and long-term resilience, setting a new standard for how high‑net‑worth families live well across generations.” said Brian Hui, Chief Customer Officer, Retail Banking and Wealth Management, HSBC Hong Kong.
Hashtag: #Humansa

The issuer is solely responsible for the content of this announcement.

About Humansa

Humansa is a leading healthcare and wellness brand dedicated to extending the human healthspan through evidence-based preventative medicine, advanced diagnostics and holistic lifestyle solutions. Founded in 2020 and headquartered in Hong Kong, Humansa operates an extensive network of centres, offering services that span health assessments, medical services, restorative therapies, wellness coaching and skin aesthetics in a refined, hospitality-inspired environment.

About HSBC and HSBC Life

The Hongkong and Shanghai Banking Corporation Limited is the founding member of the HSBC Group and one of the world’s largest banking and financial services organisations, serving customers across Asia and beyond. HSBC Life (International) Limited is a leading life insurance company, offering a comprehensive range of protection and savings solutions to individuals and corporations across the region. Together, they provide integrated banking, wealth and insurance services designed to meet the evolving financial and lifestyle needs of their clients.

By Dr. Gyan Pathak With the publication of the final rules under the Code on Wages, 2019 and Industrial Relations Code, 2020 on Friday, May 8, 2026, the Union Government of India has fully operationalized them. Apart from these, the Union Ministry of Labour and Employment has also notified the Model Standing Orders, 2026, for […]

The article India Operationalises New Labour Codes On Wages And Industrial Relations appeared first on Latest India news, analysis and reports on Newspack by India Press Agency).

The agreements were signed at the Vietnam–India Business Forum, held as part of the State visit of General Secretary and President To Lam to India, in the presence of General Secretary and President To Lam and Maharashtra Chief Minister Shri Devendra Fadnavis.

The partnerships are expected to open direct access channels to all customer segments, stimulate travel demand and experiential tourism, and ultimately position Vietnam as a “preferred destination” for India’s 1.47 billion people.

Representing India are three of the country’s most influential and trusted travel distribution channels: Thomas Cook India, SOTC Travel, and MakeMyTrip. Thomas Cook India has strong expertise in group travel, corporate travel, and large-scale MICE tourism. SOTC Travel is well known for family vacations, group tours, and mid- to high-end leisure travel. Meanwhile, MakeMyTrip, India’s leading online travel platform, has a strong advantage in reaching younger travelers, independent tourists, and digitally-driven booking behaviors.

Representing Vietnam is Vinpearl, the country’s leading hospitality, tourism, and entertainment brand, operating nearly 60 properties nationwide. Its diverse five-star “all-in-one” ecosystem offers accommodation, shopping, dining, entertainment, golf, and MICE services, making it particularly well-suited to the travel preferences of Indian visitors, including large group travel, multi-generational family vacations, and experience-rich holidays.

Through these partnerships, the parties aim to maximize each other’s strengths, enhance tourism development capabilities, and shape tailored travel products, gradually positioning Vietnam as a “preferred destination” for Indian travelers in the near future.

Speaking at the event, Ms. Ngo Thi Huong, CEO of Vinpearl, said: “India is one of the key markets in Vinpearl’s international expansion strategy. Through partnerships with leading industry players, we are not only broadening our market reach but also proactively developing products tailored to each customer segment. Vinpearl aims to strengthen its presence in the Indian market while contributing to positioning Vietnam as an attractive and distinctive destination on the global tourism map.”

Mr. Anubhav Bansal, Vice President of MakeMyTrip and representative of the three Indian partners, added: “Vinpearl operates one of the region’s leading integrated tourism and hospitality ecosystems, with a scale, product diversity, and destination experience portfolio that increasingly align with the preferences of Indian travelers. We believe Vinpearl is playing an important role in positioning Vietnam as an attractive destination for this market. Combined with the extensive distribution strengths of both sides, this partnership is expected to significantly boost Indian tourist arrivals to Vietnam in the coming years.”

India is currently the world’s most populous country, with 1.47 billion people. The country’s rapidly expanding middle class is driving a strong surge in demand for international travel.

Recognizing the strategic importance of the Indian market, Vinpearl has not only leveraged its scale and integrated “all-in-one” ecosystem but has also continuously developed specialized offerings for Indian travelers, including luxury wedding tourism, MICE travel, multi-generational family holidays, group trips, and couple getaways. In 2025, the number of Indian guests staying within the Vinpearl system surged by a record 402% year-on-year, followed by a further 335% increase during the first four months of this year compared to the same period last year.

The signing of MoUs with these three major market access partners marks the next step in Vinpearl’s strategy to sustainably grow its visitor base from the 1.47 billion-population Indian market, while also helping position Vietnam as a “preferred destination” for Indian travelers.

Hashtag: #Vinpearl

https://vinpearl.com/en

The issuer is solely responsible for the content of this announcement.

About Vinpearl

Vinpearl is Vietnam’s leading hospitality, tourism, and entertainment brand, currently operating 60 properties across 20 provinces and cities nationwide. Its ecosystem includes a network of five-star hotels and resorts in 35 provinces and cities with more than 17,300 rooms; 15 VinWonders theme parks offering attractions for all age groups; six world-class golf courses; and three international-standard convention centers and theaters under the VinPalace brand. The ecosystem also features two semi-wildlife conservation and care parks, an equestrian academy, and spectacular multi-million-dollar live performance shows in destinations such as Nha Trang and Phu Quoc, attracting millions of visitors each year.

About Thomas Cook India

Founded in 1881, Thomas Cook (India) Limited (TCIL) is one of India’s leading omnichannel travel and tourism groups, operating across foreign exchange, corporate travel, MICE, leisure travel, and value-added services.

TCIL owns and operates several major B2C and B2B brands, including Thomas Cook, SOTC, TCI, SITA, Sterling Holiday Resorts, Asian Trails, and Desert Adventures. The group has a presence in 28 countries across five continents and is one of the largest travel service networks headquartered in the Asia-Pacific region.

About SOTC Travel

Established in 1949, SOTC Travel is one of India’s oldest and most reputable travel and tourism brands. The company is part of Fairfax Financial Holdings through Thomas Cook (India) Limited (TCIL).

Operating through an omnichannel model, SOTC offers a wide range of services across leisure travel, incentive travel, and corporate travel. With more than 75 years of experience, SOTC has served millions of travelers across destinations worldwide and is recognized for its deep understanding of Indian travelers’ preferences and behaviors.

About MakeMyTrip

MakeMyTrip is India’s leading online travel booking platform, holding a dominant position in flight bookings, hotel reservations, and travel packages. With tens of millions of users and a strong digital ecosystem, MakeMyTrip covers the entire customer journey while maintaining a strong advantage in reaching younger travelers and independent tourists.